VTGN — Vistagen Therapeutics Share Price
0.000.00%
Last trade - 00:00- $60.90m
- -$27.66m
- $1.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.75 | ||
| Price to Tang. Book | 0.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 87.21 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -63.9% | ||
| Return on Equity | -46.28% | ||
| Operating Margin | -7566.52% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 1.09 | 1.11 | -0.23 | 1.06 | 0.71 | 0.43 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.
Directors
- Jon Saxe NEC (85)
- H. Ralph Snodgrass PRE (71)
- Shawn Singh CEO (58)
- Jerrold Dotson CFO (68)
- Mark Ginski SVP (49)
- Ann Cunningham OTH (53)
- Mark Smith OTH (65)
- Joanne Curley IND (53)
- Margaret Fitzpatrick IND (55)
- Jerry Gin IND (78)
- Mary Rotunno IND (61)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 6th, 2005
- Public Since
- October 18th, 2010
- No. of Shareholders
- 365
- No. of Employees
- 48
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 28,862,085
- Address
- 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.vistagen.com/
- Phone
- +1 6505773600
- Contact
- Mark Mcpartland
- Auditors
- WithumSmith Brown PC
Upcoming Events for VTGN
Q1 2026 Vistagen Therapeutics Inc Earnings Release
Vistagen Therapeutics Inc Annual Shareholders Meeting
Similar to VTGN
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Vistagen Therapeutics share price?
As of Today at 24:00 UTC, shares in Vistagen Therapeutics are trading at $2.11. This share price information is delayed by 15 minutes.
How has the Vistagen Therapeutics share price performed this year?
Shares in Vistagen Therapeutics last closed at $2.11 and the price had moved by -54.82% over the past 365 days. In terms of relative price strength the Vistagen Therapeutics share price has underperformed the S&P500 Index by -57.52% over the past year.
What are the analyst and broker recommendations for Vistagen Therapeutics?
The overall consensus recommendation for Vistagen Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vistagen Therapeutics dividend yield?
Vistagen Therapeutics does not currently pay a dividend.
Does Vistagen Therapeutics pay a dividend?
Vistagen Therapeutics does not currently pay a dividend.
When does Vistagen Therapeutics next pay dividends?
Vistagen Therapeutics does not currently pay a dividend.
How do I buy Vistagen Therapeutics shares?
To buy shares in Vistagen Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vistagen Therapeutics?
As of the previous close price of $2.11, shares in Vistagen Therapeutics had a market capitalisation of $60.90m.
Where are Vistagen Therapeutics shares listed?
Here are the trading details for Vistagen Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VTGN
What kind of share is Vistagen Therapeutics?
Based on an overall assessment of its quality, value and momentum Vistagen Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vistagen Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Vistagen Therapeutics is $13.00. That is 516.11% above the last closing price of $2.11.
Analysts covering Vistagen Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.74 for the next financial year.
Find out moreWhat is the trend in the Vistagen Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vistagen Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -23.84%.
As of the last closing price of $2.11, shares in Vistagen Therapeutics were trading -28.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vistagen Therapeutics PE Ratio?
The Vistagen Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vistagen Therapeutics?
Vistagen Therapeutics' management team is headed by:
- Jon Saxe - NEC
- H. Ralph Snodgrass - PRE
- Shawn Singh - CEO
- Jerrold Dotson - CFO
- Mark Ginski - SVP
- Ann Cunningham - OTH
- Mark Smith - OTH
- Joanne Curley - IND
- Margaret Fitzpatrick - IND
- Jerry Gin - IND
- Mary Rotunno - IND